Comparison of pharmacological inhibitors of lysine-specific demethylase 1 in glioblastoma stem cells reveals inhibitor-specific efficacy profiles

IntroductionImproved therapies for glioblastoma (GBM) are desperately needed and require preclinical evaluation in models that capture tumor heterogeneity and intrinsic resistance seen in patients. Epigenetic alterations have been well documented in GBM and lysine-specific demethylase 1 (LSD1/KDM1A)...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Lea M. Stitzlein, Achintyan Gangadharan, Leslie M. Walsh, Deokhwa Nam, Alexsandra B. Espejo, Melissa M. Singh, Kareena H. Patel, Yue Lu, Xiaoping Su, Ravesanker Ezhilarasan, Joy Gumin, Sanjay Singh, Erik Sulman, Frederick F. Lang, Joya Chandra
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-04-01
Serie:	Frontiers in Neurology
Soggetti:	histone demethylase inhibitors epigenetics lysine specific demethylase (KDM) glioblastoma drug resistance
Accesso online:	https://www.frontiersin.org/articles/10.3389/fneur.2023.1112207/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!